新橋生物 NBP 深 滬
已收盤 07-31 16:00:00 美东时间
1.60
-0.040
-2.44%
華盛通- 最 高1.65
- 今 開1.65
- 成交量 16.92万股
- 最 低 1.58
- 昨 收 1.64
- 總市值 1.85亿
- 52周最高 6.79
- 市盈率 靜 --
- 換手率 0.15%
- 52周最低 1.46
- 委 比 -68.66%
- 總股本 1.16亿
- 歷史最高 85.40
- 量 比 0.72
- 振 幅 4.27%
- 歷史最低 0.595
- 每 手 1
- 風險率 1.11%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多NovaBridge Biosciences to Hold Annual General Meeting on September 8, 2026
NovaBridge Biosciences announced it will hold its annual general meeting (AGM) on September 8, 2026, at its Shanghai office. Shareholders of record as of July 27, 2026, are entitled to attend and vote. The Company also filed its annual report on Form 20-F with the SEC and provides updates on its pipeline, including givastomig and VIS-101, which are in clinical development for various cancers and retinal diseases. The AGM materials and annual repo...
07-24 21:00
NovaBridge Biosciences Launches 2026 Omnibus Share Incentive Plan
NovaBridge Biosciences ( ($NBP) ) has provided an update. On July 13, 2026, Nov...
07-17 18:28
新桥生物任命Srishti Gupta博士为首席执行官
新桥生物（纳斯达克股票代码：NBP，下称“新桥生物”或“公司”），一家聚焦重大未满足临床需求、致力于推动创新疗法的临床阶段生物制药公司，今日宣布任命Srish...
06-30 13:36
NovaBridge Biosciences appoints Srishti Gupta as CEO
NovaBridge Biosciences (NBP) appointed Srishti Gupta as CEO and a member of its board, effective July 1, succeeding Xi-Yong (Sean) Fu, who is stepping down. Fu will remain with the company in an advis...
06-29 19:23
NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer
NovaBridge Biosciences announced the appointment of Dr. Srishti Gupta as CEO, effective July 1, 2026, succeeding Dr. Xi-Yong Fu, who will transition to an advisory role. Dr. Gupta, with over two decades of leadership in biopharmaceuticals and global health, aims to advance NovaBridge's innovative medicines, including givastomig and VIS-101, toward registration and establish strategic partnerships. NovaBridge focuses on addressing significant unme...
06-29 11:00
NovaBridge Biosciences Says FDA Grants Fast Track Designation To Givastomig In First-Line HER2-Negative Metastatic Gastric Cancer
Registrational Phase 3 Trial Expected to Begin as Early as Q4 2026 Detailed Phase 1b Data Expected to be Presented at a Major Medical Conference in H2 2026 ROCKVILLE, Md., June 16, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platfor...
06-16 19:17
NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer
NovaBridge Biosciences announced that the FDA has granted Fast Track Designation to givastomig, a CLDN18.2 x 4-1BB bispecific antibody, for the treatment of previously untreated HER2-negative advanced or metastatic gastroesophageal adenocarcinomas (GEA) with CLDN18.2 and PD-L1 positive tumors. Phase 1b data showed strong efficacy and tolerability when combined with immunochemotherapy, supporting its potential as a leading CLDN18.2-targeted therap...
06-16 11:00
NovaBridge to Present at the 2026 Jefferies Global Healthcare Conference
NovaBridge Biosciences announced that its senior management will participate in the 2026 Jefferies Global Healthcare Conference on June 4, 2026. The event will feature a company presentation at 3:10 PM ET and one-on-one investor meetings. NovaBridge, a global biotech company focused on innovative medicines, highlighted its pipeline including givastomig, a Claudin 18.2 X 4-1BB bispecific antibody for gastric cancer, and VIS-101, a dual VEGF-A X AN...
05-28 11:00
NovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
NovaBridge Biosciences announced that its management team will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. The event will feature a fireside chat at 3:30 PM ET, with a webcast available on NovaBridge's website for 90 days. NovaBridge, a global biotech company focused on accelerating innovative medicines, highlighted its pipeline, including givastomig, a Claudin 18.2 X 4-1BB bispecific antibody for...
05-12 11:00
